Sales Performance of Cresemba in Japan
Basilea Pharmaceutica Ltd, a biopharmaceutical company committed to addressing the needs of patients suffering from severe infections, has made significant strides with its antifungal product, Cresemba (isavuconazole). Recently, the company announced that the sales figures from Japan have surpassed a milestone that triggers a payment of approximately CHF 1.7 million from Asahi Kasei Pharma, its partner in this venture. This marks the second consecutive milestone payment received by Basilea in a short period.
Remarkable Growth in the Antifungal Sector
In a statement, David Veitch, the Chief Executive Officer of Basilea, expressed satisfaction with the ongoing success of Cresemba in the Japanese market. He emphasized Japan as a vital market with promising long-term growth opportunities, as the product continues to address critical needs for patients dealing with life-threatening fungal infections. The uptake of Cresemba in this key region is a testament to its effectiveness.
Global Reach and Sales Achievement
Cresemba is making waves across more than 70 countries globally. Recent statistics reveal that in the year leading up to December 2024, Cresemba achieved global in-market sales of approximately USD 562 million—a remarkable 19 percent increase year-on-year. This substantial growth solidifies Cresemba's position as the leading branded antifungal treatment for invasive fungal infections worldwide.
Details About Cresemba
Cresemba, which features isavuconazole as its active ingredient, comes in both intravenous and oral forms. To enhance its availability, Basilea has established an array of licensing and distribution agreements covering about 115 countries. In Japan, it provides vital treatment options for adults combating aspergillosis—such as invasive aspergillosis and chronic progressive pulmonary aspergillosis—as well as mucormycosis and cryptococcosis. The product is also approved in various regions, including the European Union, the United Kingdom, the United States, and numerous countries throughout Asia-Pacific.
Understanding Basilea's Commitment
Founded in the year 2000 and headquartered in Switzerland, Basilea Pharmaceutica is dedicated to the discovery and development of innovative therapies aimed effectively at serious infections. The company has successfully launched two primary hospital brands: Cresemba for invasive fungal infections and Zevtera for bacterial infections. Its pipeline includes both preclinical and clinical anti-infective candidates, showcasing their robust commitment to enhancing patient care.
Company Contact Information
For more information, individuals can reach out to:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd
Hegenheimermattweg 167b
4123 Allschwil
Switzerland
Phone: +41 61 606 1102
Email: media_relations@basilea.com | investor_relations@basilea.com
Frequently Asked Questions
What is Cresemba used for?
Cresemba is an antifungal medication used to treat severe fungal infections, including aspergillosis, mucormycosis, and cryptococcosis.
What recent achievements has Basilea reached?
Basilea recently received a milestone payment from Asahi Kasei Pharma due to strong sales performance of Cresemba in Japan.
In how many countries is Cresemba available?
Cresemba is marketed in more than 70 countries around the world, reflecting its global reach in the antifungal market.
Who is the CEO of Basilea Pharmaceutica?
The Chief Executive Officer of Basilea Pharmaceutica is David Veitch, who plays a pivotal role in the company's strategy and direction.
How can I contact Basilea for more information?
You can contact Basilea Pharmaceutica through their corporate communications head, Peer Nils Schröder, at the provided email addresses.
